Johnson & Johnson Vision today announced that results from two Phase 3 clinical studies evaluating the company's investigational antihistamine-releasing contact lens (etafilcon A with 0.019 mg ketotifen) were published in the journal Cornea. The results demonstrated that patients wearing the investigational contact lens had lower mean itching scores after their eyes were exposed to allergens compared to those wearing non-medicated control lenses, indicating that in these studies, the lenses reduced symptoms of eye itch.
The antihistamine-releasing contact lenses worn in the studies are daily disposable lenses containing ketotifen, a drug that inhibits certain substances in the body that are known to cause allergic reactions and inflammation. They were tested in two multicenter, double-masked, randomized, placebo-controlled trials that included 244 patients and used the conjunctival allergen challenge model (Ora-CAC®) to measure efficacy.
Read more: https://prn.to/2CEAc6O